Advertisement

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022

Published:November 07, 2022DOI:https://doi.org/10.1053/j.jvca.2022.11.002
      This special article is the 15th in an annual series for the Journal of Cardiothoracic and Vascular Anesthesia. The authors thank the editor-in-chief Dr. Kaplan and the editorial board for the opportunity to continue this series, namely the research highlights of the past year in the specialties of cardiothoracic and vascular anesthesiology. The major themes selected for 2022 are outlined in this introduction, and each highlight is reviewed in detail in the main body of the article. The literature highlights, in the specialties for 2022, begin with an update on COVID-19 therapies, with a focus on the temporal updates in a wide range of therapies, progressing from medical to the use of extracorporeal membrane oxygenation and, ultimately, with lung transplantation in this high-risk group. The second major theme is focused on medical cardiology, with the authors discussing new insights into the life cycle of coronary disease, heart failure treatments, and outcomes related to novel statin therapy. The third theme is focused on mechanical circulatory support, with discussions focusing on both right-sided and left-sided temporary support outcomes and the optimal timing of deployment. The fourth and final theme is an update on cardiac surgery, with a discussion of the diverse aspects of concomitant valvular surgery and the optimal approach to procedural treatment for coronary artery disease. The themes selected for this 15th special article are only a few of the diverse advances in the specialties during 2022. These highlights will inform the reader of key updates on a variety of topics, leading to the improvement of perioperative outcomes for patients with cardiothoracic and vascular disease.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martin AK
        • Feinman JW
        • Bhatt HV
        • et al.
        The year in cardiothoracic and vascular anesthesia: Selected highlights from 2021.
        J Cardiothorac Vasc Anesth. 2022; 36: 940-951
        • Tonna JE
        • Abrams D
        • Brodie D
        • et al.
        Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO).
        ASAIO J. 2021; 67: 601-610
        • Combes A
        • Schmidt M
        • Hodgson CL
        • et al.
        Extracorporeal life support for adults with acute respiratory distress syndrome.
        Intensive Care Med. 2020; 46: 2464-2476
        • Ader F
        • Bouscambert-Duchamp M
        • Hites M
        • et al.
        Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial.
        Lancet Infect Dis. 2022; 22: 209-221
        • Ali K
        • Azher T
        • Baqi M
        • et al.
        Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial.
        CMAJ. 2022; 194: E242-E251
        • Beigel JH
        • Tomashek KM
        • Dodd LE
        • et al.
        Remdesivir for the treatment of Covid-19 - Final Report.
        N Engl J Med. 2020; 383: 1813-1826
        • Consortium WHOST.
        Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses.
        Lancet. 2022; 399: 1941-1953
        • Goldman JD
        • Lye DCB
        • Hui DS
        • et al.
        Remdesivir for 5 or 10 days in patients with severe Covid-19.
        N Engl J Med. 2020; 383: 1827-1837
        • Gottlieb RL
        • Vaca CE
        • Paredes R
        • et al.
        Early remdesivir to prevent progression to severe Covid-19 in outpatients.
        N Engl J Med. 2022; 386: 305-315
        • Spinner CD
        • Gottlieb RL
        • Criner GJ
        • et al.
        Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial.
        JAMA. 2020; 324: 1048-1057
        • Crothers K
        • DeFaccio R
        • Tate J
        • et al.
        Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support.
        Eur Respir J. 2022; 602102532
        • Group RC
        • Horby P
        • Lim WS
        • et al.
        Dexamethasone in hospitalized patients with Covid-19.
        N Engl J Med. 2021; 384: 693-704
        • Ely EW
        • Ramanan AV
        • Kartman CE
        • et al.
        Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial.
        Lancet Respir Med. 2022; 10: 327-336
        • Group RC.
        Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis.
        Lancet. 2022; 400: 359-368
        • Investigators R-C
        • Gordon AC
        • Mouncey PR
        • et al.
        Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
        N Engl J Med. 2021; 384: 1491-1502
        • Kalil AC
        • Patterson TF
        • Mehta AK
        • et al.
        Baricitinib plus remdesivir for hospitalized adults with Covid-19.
        N Engl J Med. 2021; 384: 795-807
        • Marconi VC
        • Ramanan AV
        • de Bono S
        • et al.
        Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
        Lancet Respir Med. 2021; 9: 1407-1418
        • Wolfe CR
        • Tomashek KM
        • Patterson TF
        • et al.
        Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): A randomised, double-blind, double placebo-controlled trial.
        Lancet Respir Med. 2022; 10: 888-899
        • Davies A
        • Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza I
        Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome.
        JAMA. 2009; 302: 1888-1895
        • Mauri T
        • Bellani G
        • Grasselli G
        • et al.
        Patient-ventilator interaction in ARDS patients with extremely low compliance undergoing ECMO: A novel approach based on diaphragm electrical activity.
        Intensive Care Med. 2013; 39: 282-291
        • Morris AH
        • Wallace CJ
        • Menlove RL
        • et al.
        Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome.
        Am J Respir Crit Care Med. 1994; 149: 295-305
        • Peek GJ
        • Mugford M
        • Tiruvoipati R
        • et al.
        Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial.
        Lancet. 2009; 374: 1351-1363
        • Badulak J
        • Antonini MV
        • Stead CM
        • et al.
        Extracorporeal membrane oxygenation for COVID-19: Updated 2021 guidelines from the Extracorporeal Life Support Organization.
        ASAIO J. 2021; 67: 485-495
        • Ramanathan K
        • Antognini D
        • Combes A
        • et al.
        Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.
        Lancet Respir Med. 2020; 8: 518-526
        • Shekar K
        • Badulak J
        • Peek G
        • et al.
        Extracorporeal Life Support Organization coronavirus disease 2019 interim guidelines: A consensus document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers.
        ASAIO J. 2020; 66: 707-721
        • Namendys-Silva SA
        ECMO for ARDS due to COVID-19.
        Heart Lung. 2020; 49: 348-349
        • Lebreton G
        • Schmidt M
        • Ponnaiah M
        • et al.
        Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: A multicentre cohort study.
        Lancet Respir Med. 2021; 9: 851-862
        • Barbaro RP
        • MacLaren G
        • Boonstra PS
        • et al.
        Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry.
        Lancet. 2020; 396: 1071-1078
        • Ramanathan K
        • Shekar K
        • Ling RR
        • et al.
        Extracorporeal membrane oxygenation for COVID-19: A systematic review and meta-analysis.
        Crit Care. 2021; 25: 211
        • Urner M
        • Barnett AG
        • Bassi GL
        • et al.
        Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: Comparative effectiveness study.
        BMJ. 2022; 377e068723
        • Broman LM
        • Eksborg S
        • Lo Coco V
        • et al.
        Extracorporeal membrane oxygenation for COVID-19 during first and second waves.
        Lancet Respir Med. 2021; 9: e80-e81
        • Barbaro RP
        • MacLaren G
        • Boonstra PS
        • et al.
        Extracorporeal membrane oxygenation for COVID-19: Evolving outcomes from the international Extracorporeal Life Support Organization Registry.
        Lancet. 2021; 398: 1230-1238
        • Schmidt M
        • Langouet E
        • Hajage D
        • et al.
        Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris.
        Crit Care. 2021; 25: 355
        • Widmeier E
        • Wengenmayer T
        • Maier S
        • et al.
        Extracorporeal membrane oxygenation during the coronavirus disease 2019 pandemic-Continued observations from a retrospective single-center registry.
        Artif Organs. 2022; 46: 2329-2333
        • Supady A
        • Combes A
        • Barbaro RP
        • et al.
        Respiratory indications for ECMO: Focus on COVID-19.
        Intensive Care Med. 2022; 48: 1326-1337
        • Chen JY
        • Qiao K
        • Liu F
        • et al.
        Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis.
        Chin Med J (Engl). 2020; 133: 1390-1396
        • Yeung JC
        • Cypel M
        • Chaparro C
        • et al.
        Lung transplantation for acute COVID-19: The Toronto Lung Transplant Program experience.
        CMAJ. 2021; 193: E1494-E1497
        • Schaheen L
        • Bremner RM
        • Walia R
        • et al.
        Lung transplantation for coronavirus disease 2019 (COVID-19): The who, what, where, when, and why.
        J Thorac Cardiovasc Surg. 2022; 163: 865-868
        • Martin AK
        • Shah SZ
        • Guru PK
        • et al.
        Multidisciplinary approach for lung transplantation due to COVID-19.
        Mayo Clin Proc Innov Qual Outcomes. 2022; 6: 200-208
        • Kurihara C
        • Manerikar A
        • Querrey M
        • et al.
        Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant.
        JAMA. 2022; 327: 652-661
        • Lang C
        • Ritschl V
        • Augustin F
        • et al.
        Clinical relevance of lung transplantation for COVID-19 ARDS: A nationwide study.
        Eur Respir J. 2022; 602102404
        • Martin AK
        • Renew JR
        • Jayaraman AL
        • et al.
        Analysis of outcomes in lung transplantation.
        J Cardiothorac Vasc Anesth. 2019; 33: 1455-1466
        • Martin AK
        • Jayaraman AL
        • Nabzdyk CG
        • et al.
        Extracorporeal membrane oxygenation in lung transplantation: Analysis of techniques and outcomes.
        J Cardiothorac Vasc Anesth. 2021; 35: 644-661
        • Martin AK
        • Harrison BA
        • Fritz AV
        • et al.
        Intraoperative management of a hybrid extracorporeal membrane oxygenation circuit for lung transplantation.
        J Card Surg. 2020; 35: 3560-3563
        • Thomas M
        • Martin AK
        • Allen WL
        • et al.
        Lung transplantation using a hybrid extracorporeal membrane oxygenation circuit.
        ASAIO J. 2020; 66: e123-e125
      1. Aslam S. Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. Available at: https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf. Accessed August 12, 2022.

        • Cypel M
        • Keshavjee S.
        When to consider lung transplantation for COVID-19.
        Lancet Respir Med. 2020; 8: 944-946
        • Russ M
        • Menk M
        • Graw JA
        • et al.
        COVID-19 patients require prolonged extracorporeal membrane oxygenation support for survival compared with non-COVID-19 patients.
        Crit Care Explor. 2022; 4: e0671
        • Bharat A
        • Machuca TN
        • Querrey M
        • et al.
        Early outcomes after lung transplantation for severe COVID-19: A series of the first consecutive cases from four countries.
        Lancet Respir Med. 2021; 9: 487-497
        • Roach A
        • Chikwe J
        • Catarino P
        • et al.
        Lung transplantation for Covid-19-related respiratory failure in the United States.
        N Engl J Med. 2022; 386: 1187-1188
        • van der Mark SC
        • Hoek RAS
        • Hellemons ME.
        Developments in lung transplantation over the past decade.
        Eur Respir Rev. 2020; 29190132
        • Frick AE
        • Gan CT
        • Vos R
        • et al.
        Lung transplantation for acute respiratory distress syndrome: A multicenter experience.
        Am J Transplant. 2022; 22: 144-153
        • Lang C
        • Jaksch P
        • Hoda MA
        • et al.
        Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient.
        Lancet Respir Med. 2020; 8: 1057-1060
        • Roedl K
        • Jarczak D
        • Drolz A
        • et al.
        Severe liver dysfunction complicating course of COVID-19 in the critically ill: Multifactorial cause or direct viral effect?.
        Ann Intensive Care. 2021; 11: 44
        • Bharat A
        • Querrey M
        • Markov NS
        • et al.
        Lung transplantation for pulmonary fibrosis secondary to severe COVID-19.
        medRxiv. 2020; (2020:10.26.20218636. Preprint)
        • Raskin J
        • Vanstapel A
        • Verbeken EK
        • et al.
        Mortality after lung transplantation: A single-centre cohort analysis.
        Transpl Int. 2020; 33: 130-141
        • Benazzo A
        • Schwarz S
        • Muckenhuber M
        • et al.
        Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: A single centre experience.
        PLoS One. 2019; 14e0210443
        • King CS
        • Mannem H
        • Kukreja J
        • et al.
        Lung transplantation for patients with COVID-19.
        Chest. 2022; 161: 169-178
        • Leard LE
        • Holm AM
        • Valapour M
        • et al.
        Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
        J Heart Lung Transplant. 2021; 40: 1349-1379
        • Rudym D
        • Chang SH
        • Angel LF.
        Characteristics and outcomes of patients with COVID-19–associated ARDS who underwent lung transplant.
        JAMA. 2022; 327: 2454
        • Messika J
        • Schmidt M
        • Tran-Dinh A
        • et al.
        Lung transplantation for COVID-19-associated ARDS.
        Lancet Respir Med. 2021; 9: e89
        • Carr JJ
        • Jacobs Jr., DR
        • Terry JG
        • et al.
        Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death.
        JAMA Cardiol. 2017; 2: 391-399
        • Javaid A
        • Mitchell JD
        • Villines TC.
        Predictors of coronary artery calcium and long-term risks of death, myocardial infarction, and stroke in young adults.
        J Am Heart Assoc. 2021; 10e022513
        • Javaid A
        • Dardari ZA
        • Mitchell JD
        • et al.
        Distribution of coronary artery calcium by age, sex, and race among patients 30-45 years old.
        J Am Coll Cardiol. 2022; 79: 1873-1886
        • Dzaye O
        • Razavi AC
        • Dardari ZA
        • et al.
        Modeling the recommended age for initiating coronary artery calcium testing among at-risk young adults.
        J Am Coll Cardiol. 2021; 78: 1573-1583
        • Zheng Y
        • Joyce BT
        • Hwang SJ
        • et al.
        Association of cardiovascular health through young adulthood with genome-wide DNA methylation patterns in midlife: The CARDIA study.
        Circulation. 2022; 146: 94-109
        • Hasbani NR
        • Ligthart S
        • Brown MR
        • et al.
        American Heart Association's Life's Simple 7: Lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease.
        Circulation. 2022; 145: 808-818
        • Tsao CW
        • Aday AW
        • Almarzooq ZI
        • et al.
        Heart disease and stroke statistics-2022 update: A report from the American Heart Association.
        Circulation. 2022; 145: e153-e639
        • Virani SS
        • Alonso A
        • Aparicio HJ
        • et al.
        Heart disease and stroke statistics-2021 update: A report from the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Butler J
        • Anker SD
        • Filippatos G
        • et al.
        Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-Reduced trial.
        Eur Heart J. 2021; 42: 1203-1212
        • Tsampasian V
        • Baral R
        • Chattopadhyay R
        • et al.
        The Role of SGLT2 Inhibitors in heart failure: A systematic review and meta-analysis.
        Cardiol Res Pract. 2021; 20219927533
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Butler J
        • Filippatos G
        • Jamal Siddiqi T
        • et al.
        Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
        Circulation. 2022; 145: 184-193
        • Packer M
        • Anker SD
        • Butler J
        • et al.
        Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Bohm M
        • Anker SD
        • Butler J
        • et al.
        Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure.
        J Am Coll Cardiol. 2021; 78: 1337-1348
        • Komajda M
        • Bohm M
        • Borer JS
        • et al.
        Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
        Eur J Heart Fail. 2014; 16: 810-816
        • Stone NJ
        • Robinson JG
        • Lichtenstein AH
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Lloyd-Jones DM
        • Leip EP
        • Larson MG
        • et al.
        Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.
        Circulation. 2006; 113: 791-798
        • Nelson AJ
        • Haynes K
        • Shambhu S
        • et al.
        High-intensity statin use among patients with atherosclerosis in the U.S.
        J Am Coll Cardiol. 2022; 79: 1802-1813
        • Koskinas KC
        • Siontis GCM
        • Piccolo R
        • et al.
        Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials.
        Eur Heart J. 2018; 39: 1172-1180
        • Libby P.
        Mechanisms of acute coronary syndromes and their implications for therapy.
        N Engl J Med. 2013; 368: 2004-2013
        • Raber L
        • Ueki Y
        • Otsuka T
        • et al.
        Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: The PACMAN-AMI randomized clinical trial.
        JAMA. 2022; 327: 1771-1781
        • Sabatine MS
        • Giugliano RP
        • Keech AC
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Schwartz GG
        • Steg PG
        • Szarek M
        • et al.
        Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N Engl J Med. 2018; 379: 2097-2107
        • Nicholls SJ
        • Puri R
        • Anderson T
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial.
        JAMA. 2016; 316: 2373-2384
        • Elia E
        • Iannaccone M
        • D'Ascenzo F
        • et al.
        Short term outcomes of Impella circulatory support for high-risk percutaneous coronary intervention a systematic review and meta-analysis.
        Catheter Cardiovasc Interv. 2022; 99: 27-36
        • Panuccio G
        • Neri G
        • Macri LM
        • et al.
        Use of Impella device in cardiogenic shock and its clinical outcomes: A systematic review and meta-analysis.
        Int J Cardiol Heart Vasc. 2022; 40101007
        • Iannaccone M
        • Franchin L
        • Hanson ID
        • et al.
        Timing of impella placement in PCI for acute myocardial infarction complicated by cardiogenic shock: An updated meta-analysis.
        Int J Cardiol. 2022; 362: 47-54
        • Miyashita S
        • Banlengchit R
        • Marbach JA
        • et al.
        Left ventricular unloading before percutaneous coronary intervention is associated with improved survival in patients with acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis.
        Cardiovasc Revasc Med. 2022; 39: 28-35
        • Slaughter MS
        • Rogers JG
        • Milano CA
        • et al.
        Advanced heart failure treated with continuous-flow left ventricular assist device.
        N Engl J Med. 2009; 361: 2241-2251
        • Goldstein DJ
        • Meyns B
        • Xie R
        • et al.
        Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices.
        J Heart Lung Transplant. 2019; 38: 352-363
        • Kumar S
        • Derbala MH
        • Nguyen DT
        • et al.
        A multi-institutional retrospective analysis on impact of RV acute mechanical support timing after LVAD implantation on 1-year mortality and predictors of RV acute mechanical support weaning.
        J Heart Lung Transplant. 2022; 41: 244-254
        • Beller JP
        • Mehaffey JH
        • Wegermann ZK
        • et al.
        Strategies for mechanical right ventricular support during left ventricular assist device implant.
        Ann Thorac Surg. 2022; 114: 484-491
        • Reid G
        • Mork C
        • Gahl B
        • et al.
        Outcome of right ventricular assist device implantation following left ventricular assist device implantation: Systematic review and meta-analysis.
        Perfusion. 2021; (2676591211024817)
        • Gammie JS
        • Chu MWA
        • Falk V
        • et al.
        Concomitant tricuspid repair in patients with degenerative mitral regurgitation.
        N Engl J Med. 2022; 386: 327-339
        • Pagnesi M
        • Montalto C
        • Mangieri A
        • et al.
        Tricuspid annuloplasty versus a conservative approach in patients with functional tricuspid regurgitation undergoing left-sided heart valve surgery: A study-level meta-analysis.
        Int J Cardiol. 2017; 240: 138-144
        • Cetinkaya A
        • Ganchewa N
        • Hein S
        • et al.
        Long-term outcomes of concomitant tricuspid valve repair in patients undergoing mitral valve surgery.
        J Cardiothorac Surg. 2020; 15: 210
        • John R
        • Kanwar MK
        • Cleveland Jr., JC
        • et al.
        Concurrent valvular procedures during left ventricular assist device implantation and outcomes: A comprehensive analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 trial portfolio.
        J Thorac Cardiovasc Surg. 2022; (S0022-5223(22)00498-6)
        • Briasoulis A
        • Yokoyama Y
        • Kuno T
        • et al.
        In-hospital outcomes of left ventricular assist device implantation and concomitant valvular surgery.
        Am J Cardiol. 2020; 132: 87-92
        • Loforte A
        • de By T
        • Gliozzi G
        • et al.
        Impact of concomitant cardiac valvular surgery during implantation of continuous-flow left ventricular assist devices: A European registry for patients with mechanical circulatory support (EUROMACS) analysis.
        Artif Organs. 2022; 46: 813-826
        • Riebandt J
        • Schaefer A
        • Wiedemann D
        • et al.
        Concomitant cardiac surgery procedures during left ventricular assist device implantation: Single-centre experience.
        Ann Cardiothorac Surg. 2021; 10: 248-254
        • Zhang H
        • Liu Y
        • Qiu S
        • et al.
        Short-term and long-term survival after revascularization with or without mitral valve surgery of patients with ischemic mitral valve regurgitation: A meta-analysis.
        Med Sci Monit. 2015; 21: 3784-3791
        • Chatterjee S
        • Tripathi B
        • Virk HU
        • et al.
        Does surgical repair of moderate ischemic mitral regurgitation improve survival? A systematic review.
        Curr Cardiol Rep. 2016; 18: 22
        • El-Hag-Aly MA
        • El Swaf YF
        • Elkassas MH
        • et al.
        Moderate ischemic mitral incompetence: Does it worth more ischemic time?.
        Gen Thorac Cardiovasc Surg. 2020; 68: 492-498
        • Ullah W
        • Gul S
        • Saleem S
        • et al.
        Trend, predictors, and outcomes of combined mitral valve replacement and coronary artery bypass graft in patients with concomitant mitral valve and coronary artery disease: A National Inpatient Sample database analysis.
        Eur Heart J Open. 2022; 2 (oeac002)
        • Fearon WF
        • Zimmermann FM
        • De Bruyne B
        • et al.
        Fractional flow reserve-guided PCI as compared with coronary bypass surgery.
        N Engl J Med. 2022; 386: 128-137
        • Tonino PA
        • De Bruyne B
        • Pijls NH
        • et al.
        Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
        N Engl J Med. 2009; 360: 213-224
        • Holm NR
        • Makikallio T
        • Lindsay MM
        • et al.
        Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: Updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
        Lancet. 2020; 395: 191-199
        • Sabatine MS
        • Bergmark BA
        • Murphy SA
        • et al.
        Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: An individual patient data meta-analysis.
        Lancet. 2021; 398: 2247-2257
        • Giustino G
        • Serruys PW
        • Sabik 3rd, JF
        • et al.
        Mortality after repeat revascularization following PCI or CABG for left main disease: The EXCEL trial.
        JACC Cardiovasc Interv. 2020; 13: 375-387
        • Sun LY
        • Gaudino M
        • Chen RJ
        • et al.
        Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting.
        JAMA Cardiol. 2020; 5: 631-641